Diagnostic performance of different antibody tests and cytokines in predicting coeliac disease in patients with NAFLD
| Cytokine | Sensitivity | Specificity | AUC | Positive prepvdictive value | Negative predictive value |
| TTGA (95% CI) | 96.02% (92.80% to 98.07%) | 90.62% (88.83% to 95.43%) | 0.94 (0.90 to0.96) | 92.34% (88.76% to 94.84%) | 96.17% (93.18% to 97.88%) |
| EMA IgA (95% CI) | 97% (91% to99%) | 88% (65% to92%) | 0.91 (0.85 to0.97) | 89% (78% to94%) | 91% (79% to97%) |
| TNF-α (95% CI) | 95.60% (92.26% to 97.78%) | 91.91% (88.01% to 94.86%) | 0.93 (0.89 to 0.96) | 91.57% (87.91% to 94.20%) | 95.79%–92.72% to 97.59 |
| IL-1 (95% CI) | 88.51% (84.00% to 92.11%) | 89.29% (85.06% to 92.65%) | 0.89 (0.86 to 0.91) | 88.51% (84.56% to 91.55%) | 89.29% (85.58% to 92.12%) |
| IL-6 (95% CI) | 95.26% (91.46% to 97.70%) | 83.11% (78.40% to 87.16%) | 0.89 (0.86 to 0.92) | 79.76% (75.39% to 83.53%) | 96.17% (93.19% to 97.88%) |
| IL-10 (95% CI) | 69.35% (63.37% to 74.89%) | 52.38% (44.55% to 60.13%) | 0.61 (0.56 to 0.66) | 69.35% (65.44% to 73.00%) | 52.38% (46.57% to 58.12%) |
| IL-15 (95% CI) | 95.85% (92.50% to 97.99%) | 89.32% (85.11% to 92.68%) | 0.93 (0.90 to 0.95) | 88.51% (84.58% to 91.53%) | 96.17% (93.18% to 97.88%) |
| IL-17 (95% CI) | 94.72%–91.29% to 97.08% | 96.11% (92.96% to 98.12%) | 0.95 (0.93 to 0.97) | 96.17% (93.18% to 97.88%) | 94.64%–91.37% to 96.71% |
| TTGA plus EMA IgA (95% CI) | 98% (90% to99%) | 95% (75% to97%) | 92% (82% to95%) | 93% (81% to98%) | |
| TTGA+TNF-α (95% CI) | 96.24% (93.20% to 98.18%) | 98.05% (95.50% to 99.36%) | 0.97 (0.95 to 0.98) | 98.08% (95.55% to 99.19%) | 96.17% (93.18% to 97.88%) |
| TTGA+IL-15 (95% CI) | 97.65% (94.95% to 99.13%) | 95.52% (92.31% to 97.67%) | 0.97 (0.95 to 0.98) | 95.40% (92.27% to 97.30%) | 97.71% (95.08% to 98.95%) |
| TTGA+IL-17 (95% CI) | 98.10% (95.62% to 99.38%) | 98.84% (96.65% to 99.76%) | 0.98 (0.97 to 0.99) | 98.85% (96.54% to 99.62%) | 98.08% (95.55% to 99.19%) |
AUC, area under the curve; EMA IgA, endomysial antibody IgA; IL, interleukin; NAFLD, non-alcoholic fatty liver disease; TNF-α, tumour necrosis factor-alpha; TTGA, tissue transglutaminase antibody.